Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795009 · ClinicalTrials.gov registry record · Phase 1
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
A Phase 1 study of Endometrial Cancer and Uterine Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT06795009 is a Phase 1 study of Endometrial Cancer and Uterine Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 36 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06795009, a Phase 1 study of Endometrial Cancer and Uterine Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Zanzalintinib
Study Locations (4)
California
- University of California, San Francisco - San Francisco
Missouri
- Washington University School of Medicine - St Louis
New Mexico
- University of New Mexico - Albuquerque
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2035-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06795009
The ClinicalTrials.gov registry entry for NCT06795009 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT06795009 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Missouri, New Mexico.
Frequently Asked Questions
What is clinical trial NCT06795009 about?
NCT06795009 is a clinical study titled "Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer". The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
What is the current status of trial NCT06795009?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-10-17. Estimated completion is 2035-04-30.
What conditions does trial NCT06795009 study?
This clinical trial studies the following conditions: Endometrial Cancer, Uterine Cancer.
What interventions are being tested in trial NCT06795009?
The interventions under investigation include: Paclitaxel (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06795009?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795009 being conducted?
This trial has 4 study locations across California, Missouri, New Mexico, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.